Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 USD | -3.64% | -5.86% | -88.24% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Business Summary
Number of employees: 41
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Paul Eckburg
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-31 |
Jennifer Huber
LAW | General Counsel | - | - |
Josh Eizen
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 19-10-31 | |
Kevin Krause
PRN | Corporate Officer/Principal | 49 | 21-07-31 |
Sanjay Chanda
PRN | Corporate Officer/Principal | 59 | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Director/Board Member | 58 | 22-05-08 | |
Robin Readnour
BRD | Director/Board Member | 59 | 19-10-31 |
Stephanie Wong
BRD | Director/Board Member | 50 | 21-03-31 |
Kabeer Aziz
BRD | Director/Board Member | 34 | 19-10-31 |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Gilbert Marks
BRD | Director/Board Member | 66 | 20-01-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,829,040 | 22,107,490 ( 74.11 %) | 0 | 74.11 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.95% | 73.68M | |
+23.37% | 47.02B | |
+49.90% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- ANTX Stock
- Company AN2 Therapeutics, Inc.